^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    anastrozole

    Company:
    Generic mfg.
    Drug class:
    Aromatase inhibitor
    Related drugs:
    4d
    OPERA-01: OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=510, Recruiting, Olema Pharmaceuticals, Inc. | N=370 --> 510
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative • ESR1 mutation
    |
    fulvestrant • letrozole • anastrozole • exemestane • palazestrant (OP-1250)
    5d
    HCC 21-208: Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ (clinicaltrials.gov)
    P1, N=50, Recruiting, Finn, Olivera, PhD | Trial completion date: Aug 2028 --> Mar 2029 | Trial primary completion date: Jan 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    MUC1 (Mucin 1)
    |
    tamoxifen • letrozole • anastrozole • exemestane • Hiltonol (poly-ICLC)
    6d
    Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers (clinicaltrials.gov)
    P2, N=30, Recruiting, Ruth O'Regan | Trial completion date: Jan 2026 --> Jul 2027 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • ER positive • PGR positive
    |
    Herceptin (trastuzumab) • Nerlynx (neratinib) • letrozole • anastrozole
    6d
    Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, University of California, Irvine | Active, not recruiting --> Recruiting | Trial completion date: Dec 2028 --> Dec 2031 | Trial primary completion date: Dec 2025 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    PGR (Progesterone receptor)
    |
    Verzenio (abemaciclib) • fulvestrant • anastrozole
    13d
    Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov)
    P3, N=5018, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2032 --> Jan 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    14d
    Characteristic Hepatic Atrophy in Abemaciclib-Induced Liver Injury: A Comparative Review of Three Cases. (PubMed, Hepatol Res)
    This report is the first highlighting the imaging characteristics of rapid-onset hepatic atrophy associated with abemaciclib-induced liver injury. These findings may provide useful insights for distinguishing abemaciclib-induced liver injury from other etiologies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole
    18d
    FALCON: A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (clinicaltrials.gov)
    P3, N=462, Completed, AstraZeneca | Trial completion date: Aug 2027 --> Jan 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    fulvestrant • anastrozole
    18d
    Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases (clinicaltrials.gov)
    P=N/A, N=3883, Completed, Brigham and Women's Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    PGR positive • EGFR negative
    |
    Verzenio (abemaciclib) • letrozole • anastrozole
    18d
    MECCA: Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=263, Completed, Sun Yat-sen University | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    capecitabine • letrozole • anastrozole • exemestane
    21d
    CLEE011O12001: A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. (2022-503001-38-01)
    P2/3, N=172, Active, not recruiting, Novartis Pharma AG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • PGR positive
    |
    Kisqali (ribociclib) • letrozole • anastrozole • exemestane • goserelin acetate • leuprolide acetate for depot suspension
    22d
    TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    HER-2 negative • HER-2 expression
    |
    paclitaxel • fulvestrant • letrozole • Herzuma (trastuzumab-pkrb) • anastrozole • exemestane • Trazimera (trastuzumab-qyyp) • denifanstat (TVB-2640)
    28d
    UC-BCG-2409/BIG 2402: Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer (2024-519655-28-00)
    P2/3, N=2270, Not yet recruiting, Unicancer
    New P2/3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • HR positive • HER-2 negative • HER-2 expression • ER negative
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    paclitaxel • docetaxel • tamoxifen • doxorubicin hydrochloride • cyclophosphamide • letrozole • epirubicin • anastrozole • exemestane • triptorelin • goserelin acetate • leuprolide acetate for depot suspension